-
Revue Medicale Suisse Sep 2005Perimenopause (and not the entire postmenopausal period) is a period at risk for depression. Menopause is a psychosocial and physiologic reality whose neurobiological... (Review)
Review
Perimenopause (and not the entire postmenopausal period) is a period at risk for depression. Menopause is a psychosocial and physiologic reality whose neurobiological aspects are often under-estimated. Various disturbances, such as hot flushes and, at least in part, depressive disorders, are related to this neurobiological dimension. When the depression is minor, hormone replacement therapy may be an adequate treatment. Keeping in mind the complex interactions that may occur between endogenous and exogenous progestins at the neuronal level, we would recommend a physiologic replacement using transdermal estradiol and vaginal progesterone. When the depression is major, present data do not support the possibility of using hormone replacement therapy instead of antidepressants.
Topics: Antidepressive Agents; Depressive Disorder; Female; Hormone Replacement Therapy; Humans; Middle Aged; Perimenopause
PubMed: 16223218
DOI: No ID Found -
Clinical Obstetrics and Gynecology Jun 2005
Review
Topics: Activins; Algorithms; Female; Hormones; Humans; Hysterectomy; Inhibin-beta Subunits; Inhibins; Menstrual Cycle; Perimenopause; Uterine Hemorrhage
PubMed: 15805788
DOI: 10.1097/01.grf.0000159537.89102.97 -
Psychoneuroendocrinology Apr 2021Irritability is a highly burdensome complaint, commonly, but not universally, linked with depressive symptoms. While increased variability in estradiol has been...
OBJECTIVE
Irritability is a highly burdensome complaint, commonly, but not universally, linked with depressive symptoms. While increased variability in estradiol has been associated with depressive symptoms during perimenopause, more insight is needed into reproductive hormone dynamics and other factors that predispose perimenopausal women to irritable mood.
METHODS
Among 50 mildly depressed perimenopausal women (mean (SD) age 48.4 (3.9) years), severity of irritability symptoms (on Symptom Questionnaire Hostility subscale, range 0-23) was assessed weekly for eight weeks, concurrent with potential predictors. Associations between these were examined using generalized estimating equating models.
RESULTS
Most women (82.0%) reported having moderate to severe irritability at least once. However, the severity of irritability was highly variable from week-to-week (between-subject mean coefficient of variation [CV] 72.9% and within-subject mean CV 63.7%). In multivariate analyses, less variable serum estradiol levels (standardized β within-person CV -0.23 95%CI [-0.32, -0.14], p < 0.001), greater depression severity (0.45 [0.35, 0.56], p < 0.001), younger age (-0.23, [-0.28, -0.09], p < 0.001), and more frequent vasomotor symptoms (0.14 [0.05, 0.23], p = 0.002) were associated with more irritability. Depression severity explained the largest portion of the variance in irritability, but still not more than 20.3%. Neither crude values, weekly change in, or variability of progesterone or FSH levels were associated with irritability.
CONCLUSIONS
Irritability was highly prevalent among mildly depressed perimenopausal women. In contrast to depressive symptoms, decreased rather than increased variability in estradiol levels was associated with more irritability. This highlights that irritable mood can be disentangled from depressive symptoms in perimenopausal women and might be linked with different estradiol dynamics.
Topics: Depression; Estradiol; Female; Humans; Irritable Mood; Middle Aged; Perimenopause; Progesterone
PubMed: 33493755
DOI: 10.1016/j.psyneuen.2021.105128 -
Skin Research and Technology : Official... Jan 2024
Topics: Female; Humans; Perimenopause; Rosacea
PubMed: 38221784
DOI: 10.1111/srt.13542 -
Menopause (New York, N.Y.) Mar 2016
Topics: Depression; Depressive Disorder; Humans; Perimenopause; Surveys and Questionnaires
PubMed: 26886882
DOI: 10.1097/GME.0000000000000606 -
Annals of Neurology Jun 2019To examine the longitudinal course of vasomotor symptoms (VMS) in women with a history of migraine in comparison to women without a history of migraine disease.
OBJECTIVE
To examine the longitudinal course of vasomotor symptoms (VMS) in women with a history of migraine in comparison to women without a history of migraine disease.
METHODS
The study sample consisted of 467 women with a self-reported prior migraine diagnosis and 2,466 women without prior migraine diagnosis who were assessed longitudinally during menopausal transition as part of the Study of Women's Health Across the Nation. Linear mixed regression models with backward elimination were used to evaluate longitudinal associations between VMS and migraine while adjusting for baseline and time-varying demographic, socioeconomic, psychological, and reproductive factors. Additional analyses were performed to further assess the specificity of the association between migraine and VMS that included evaluating the association between migraine and vaginal dryness and between back pain and VMS.
RESULTS
A history of migraine predicted an increased frequency of VMS but not vaginal dryness during menopausal transition. Significant interaction between history of migraine and menopausal status for the prediction of VMS was also identified. Burden of VMS was found to be higher during late-stage perimenopause in women with migraine. In contrast, the history of back pain did not predict the frequency of VMS.
INTERPRETATION
This is the first study to delineate that a history of migraine predicts an increased frequency of VMS in women during menopausal transition. Hypothalamic abnormalities and thermoregulatory dysfunction against a milieu of decreasing estradiol concentrations during menopausal transition may explain the increased frequency of VMS in migraineurs during menopausal transition. ANN NEUROL 2019;85:865-874.
Topics: Adult; Female; Follow-Up Studies; Hot Flashes; Humans; Longitudinal Studies; Middle Aged; Migraine Disorders; Perimenopause; Prospective Studies; Vasomotor System
PubMed: 30937949
DOI: 10.1002/ana.25476 -
The Australian and New Zealand Journal... Nov 2016
Topics: Antidepressive Agents; Depressive Disorder; Drug Therapy, Combination; Estrogen Receptor Modulators; Female; Hormone Replacement Therapy; Humans; Middle Aged; Norpregnenes; Perimenopause
PubMed: 27698111
DOI: 10.1177/0004867416671597 -
Menopause (New York, N.Y.) Nov 2023Weight gain and unfavorable body composition are prevalent among midlife/older women throughout menopause. These shifts may negatively impact health, well-being, and...
OBJECTIVES
Weight gain and unfavorable body composition are prevalent among midlife/older women throughout menopause. These shifts may negatively impact health, well-being, and longevity. Efforts to attenuate weight and body composition changes are traditionally driven by manipulation of diet and/or exercise; however, sustained results are limited, possibly because the full spectrum of biobehavioral systems is not addressed by diet and exercise alone. We propose a biobehavioral model detailing mechanisms of body composition decline among perimenopausal women and the associated components of Meditative Movement (ie, tai chi, qigong, yoga) that address each of these factors.
METHODS
Based on our previous work and extensive review of the literature, we developed a multifactorial and multidimensional biobehavioral model including factors that most directly relate to body composition among perimenopausal women: 1) psychological (ie, stress and mood, mindfulness and self-compassion, body awareness), 2) behavioral (ie, sleep, physical activity, eating behaviors), and 3) physiological (ie, cortisol, estrogen). Relationships between each factor, Meditative Movement practice components, and predicted effects on body composition were explored in detail.
RESULTS
Our model describes select psychological, behavioral, and physiological factors, and potential mechanistic pathways of Meditative Movement practice driving improved changes in body composition and weight outcomes for perimenopausal women.
CONCLUSIONS
The proposed model details a novel, evidence-supported means to reduce the risk of deleterious shifts in body composition throughout perimenopause and menopause thereafter. We suggest that these changes may occur directly and/or indirectly through psychological, behavioral, and physiological mechanisms that facilitate the desired changes in body composition.
Topics: Aged; Female; Humans; Biobehavioral Sciences; Body Composition; Menopause; Perimenopause; Tai Ji; Middle Aged
PubMed: 37788427
DOI: 10.1097/GME.0000000000002262 -
CMAJ : Canadian Medical Association... Jul 2023
Topics: Female; Humans; Perimenopause
PubMed: 37524397
DOI: 10.1503/cmaj.148952-l -
International Journal of Cardiology Aug 2024
Topics: Humans; Female; Coronary Angiography; Perimenopause; Computed Tomography Angiography; Coronary Artery Disease; Male; Sex Factors; Middle Aged
PubMed: 38782073
DOI: 10.1016/j.ijcard.2024.132193